|
|
|
|
|
|
|
|
full text (pdf)
May 18, 2016
We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profiling (CGP; next-generation sequencing, 236 genes). Ofthe 500 patients enrolled, 188 (37.6%) received either matched (N=122/188, 65%) or unmatched therapy (N=66/188, 35%). The most common reasons that patients were not evaluable for treatment included insufficient tissue, death, o rhospice transfer. The median number of molecular alterations per patient was five (range, 1-14); median number of prior therapies, four. The most common diagnoses were ovarian cancer (18%), breast cancer (16%),sarcoma (13%), and renal cancer (7%). Of the 339 successfully-profiledpatients, 317 (93.5%) had at least one potentially actionable alteration. …….Collectively, this study offers a clinical proof of concept for the utility of CGP in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.